Share
371 Posts.
lightbulb Created with Sketch. 792
clock Created with Sketch. 16/03/21
23:45
Share
Originally posted by Showtime:
↑
Just found this on Facebook - interesting reading.A significant impact on back pain Mesoblast 15 March 2021 Next events FDA guidance on clinical programs While rexlemestrocel-L showed a significant impact on pain , the primary endpoint was a composite responder analysis (at the 24-month time point) involving pain (via VAS) and the Oswestry Disability Index (ODI). This endpoint was not met and a new trial, with a pain-focused endpoint, might be necessary (although opioids, the current mainstay of treatment, have not shown a functional benefit either and additionally, rexlemestrocel-L appears to be opioid sparing (40% reduction)).US$110m private placement led by the principals of SurgCenter Development , one of the largest private operators of ambulatory surgical centers in the United States specializing specifically in spine, orthopedic and joint procedures. This investment provides some validation for the back pain data from medical specialists familiar with treating back pain.Heart failure trial hits 3P-MACEThis report has been commissioned by Mesoblast and prepared and issued by Edison
Expand
Well I take this as a very positive note. The upside nicely downplayed. It is so understated it makes you wonder if the author is English?
(20min delay)